Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer

•This multicenter study compared olaparib and niraparib in newly diagnosed BRCA-mutated ovarian cancer.•The study found no significant difference in PFS, TFST, or OS between two groups in the matched cohort.•Higher thrombocytopenia and neutropenia rates with niraparib suggest individualized PARP inhibitor selection.